|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
Horizon Therapeutics Acquisition a Good Deal for Amgen [December 12, 2022 @ Seeking Alpha]
Amgen Still A Buy After Joining The Dow [September 5, 2020 @ Seeking Alpha]
Amgen A Buy On Otezla Revenue [April 23, 2020 @ Seeking Alpha]
| 2024 | |||
| Amgen Q1 2024 Call Notes |
Amgen Q2 2024 Call Notes |
Amgen Q3 2024 Call Notes |
|
| May 2, 2024 | Aug. 6, 2024 | Oct. 30, 2024 | |
| 2023 | |||
| Amgen Q1 2023 Call Notes |
Amgen Q2 2023 Call Notes |
Amgen Q3 2023 Call Notes |
Amgen Q4 2023 Call Notes |
| April 27, 2023 | Aug. 3, 2023 | Oct. 31, 2023 | Feb. 6, 2024 |
| 2022 | |||
| Amgen Q1 2022 Call Notes |
Amgen Q2 2022 Call Notes |
Amgen Q3 2022 Call Notes |
Amgen Q4 2022 Call Notes |
| April 27, 2022 | August 4, 2022 | Nov. 3, 2022 | January 31, 2023 |
| 2021 | |||
| Amgen Q1 2021 Call Notes |
Amgen Q2 2021 Call Notes |
Amgen Q3 2021 Call Notes |
Amgen Q4 2021 Call Notes |
| April 27, 2021 | Aug. 3, 2021 | Nov. 2, 2021 | Feb. 8, 2022 |
| 2020 | |||
| Amgen Q1 2020 Call Notes |
Amgen Q2 2020 Call Notes |
Amgen Q3 2020 Call Notes |
Amgen Q4 2020 Call Notes |
| April 30, 2020 | July 28, 2020 | Oct. 28, 2020 | Feb. 2, 2021 |
| 2019 | |||
| Amgen Q1 2019 Call Notes |
Amgen Q2 2019 Call Notes |
Amgen Q3 2019 Call Notes |
Amgen Q4 2019 Call Notes |
| April 30, 2019 | July 30, 2019 | Oct. 29, 2019 | Jan. 30, 2020 |
2018 |
|||
April 24, 2018 |
July 26, 2018 |
Oct. 30, 2018 |
Jan. 29, 2019 |
2017 |
|||
April 26, 2017 |
July 25, 2017 |
October 25, 2017 |
February 1, 2018 |
2016 |
|||
04/28/2016 |
07/27/2016 |
10/27/2016 |
02/02/2017 |
2015 |
|||
04/21/2015 |
07/30/2015 |
10/28/2015 |
01/28/2016 |
2014 |
|||
4/22/2014 |
07/29/2014 |
10/27/2014 |
01/27/2015 |
2013 |
|||
Not available |
|||
07/30/2013 |
10/22/2013 |
01/28/2014 |
|
Amgen's AMG 510 Targeted Cancer Therapy [October 4, 2019 @ Seeking Alpha]
Amgen Evenity Approval Makes It A Hold [April 18, 2019 @ Seeking Alpha]
Amgen Should Rebound [June 20, 2018 @ Seeking Alpha]
BiTE Amgen for Long-term Returns [December 16, 2017 @ Seeking Alpha]
Amgen Valuation Now Excludes Potential Repatha Revenues [February 13, 2016]
FDA Approves Repatha [Amgen press release August 27, 2015]
Amgen 2014 Business Review Notes October 28, 2014
Amgen initial purchase March 24, 2014
Amgen with Onyx Pharmaceuticals: Long Term Analysis September 4, 2013
Amgen Valuation [blog 12/3/2007]
I did not follow Amgen closely between the end of 2008 and mid-2013. I did own Onyx Pharmaceuticals during most of that time.
2008 |
|||
 |
|
|
|
Q3 2008 |
Q2 2008 |
Q1 2008 |
Q4 2007 |
10/22/2008 |
07/28/2008 |
04/24/2008 |
1/24/2008 |
2007 |
|||
|
|
|
|
10/24/2007 |
07/26/2007 |
4/23/2007 |
|
Q3 2007 |
Q2 2007 |
Q1 2007 |
|
Amgen is a biotechnology therapeutics company selling a variety of drugs, notably Arenesp, Epogen and Enbrel.
Amgen Web site:
Disclaimer: My analyst summaries may include both my condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but its possible. I am simply sharing my personal notes, not advising anyone about investments.
Copyright 2024 William P. Meyers